Description
PT-141 ™
PT-141 ™, also known as Bremelanotide, is a revolutionary peptide therapy designed to address hypoactive sexual desire disorder (HSDD) in women and studied for erectile dysfunction (ED) in men. Unlike traditional PDE5 inhibitors (Viagra, Cialis), PT‑141™ works directly on the central nervous system pathways, stimulating sexual desire rather than vascular blood flow. Approved by the FDA in 2019 under the brand name Vyleesi®, PT‑141™ represents a new frontier in sexual health.
- Definition: A synthetic melanocortin receptor agonist peptide.
- Origin: Derived from Melanotan II, modified to reduce tanning effects while enhancing sexual function.
- FDA Approval: Approved in 2019 for HSDD in premenopausal women.
- Brand Name: Marketed as Vyleesi®.
PT-141 ™ Mechanism of Action:
PT‑141™ activates melanocortin receptors (MC3 and MC4) in the brain.
- Neurogenic stimulation: Enhances sexual desire by acting on the hypothalamus.
- Different from PDE5 inhibitors: Works on neural pathways, not vascular blood flow.
- Rapid onset: Effects begin within 30–60 minutes, lasting up to 12 hours.
PT-141 ™ Dosage and Administration:
| Aspect |
Details |
| Standard dosage |
1.75 mg subcutaneous injection |
| Frequency |
Max 1 dose per 24h, 8 doses per month |
| Administration |
Injected in thigh or abdomen |
| Onset time |
30–60 minutes |
| Duration |
8–12 hours |
Benefits of PT‑141™
| Benefit |
Explanation |
| Female sexual dysfunction |
FDA‑approved for HSDD, improves libido and satisfaction |
| Male erectile dysfunction |
Studied for men unresponsive to PDE5 inhibitors |
| Psychological confidence |
Reduces anxiety and enhances sexual confidence |
| Neurogenic stimulation |
Works on brain pathways instead of vascular system |
| Rapid onset |
Effects within 30–60 minutes |
Side Effects and Safety
| Category |
Examples |
| Common side effects |
Nausea, flushing, headache, injection site irritation |
| Moderate risks |
Increased blood pressure, dizziness |
| Serious risks |
Contraindicated in uncontrolled hypertension or cardiovascular disease |
| Long‑term considerations |
Limited chronic safety data, requires monitoring |
Research Applications
- Sexual health: Female HSDD, male ED.
- Mental health: Studied for mood regulation and depression.
- Combination therapy: Explored with PDE5 inhibitors for enhanced effect.
Comparison with Other Therapies
| Therapy |
Mechanism |
Use Case |
| PT‑141™ |
Melanocortin receptor agonist |
Neural stimulation of sexual desire |
| Viagra (Sildenafil) |
PDE5 inhibitor |
Erectile dysfunction via vascular blood flow |
| Cialis (Tadalafil) |
PDE5 inhibitor |
Longer duration vascular support |
| Addyi (Flibanserin) |
Serotonin receptor modulator |
Female sexual desire disorder |
Frequently Asked Questions (FAQ)
- What is PT‑141™ used for? FDA‑approved for HSDD in premenopausal women.
- How is PT‑141™ administered? Subcutaneous injection in thigh or abdomen.
- Is PT‑141™ safe? Generally safe under medical supervision, but nausea and blood pressure changes are common.
- Can PT‑141™ be used by men? Studied for erectile dysfunction, though not FDA‑approved for men.
- How quickly does PT‑141™ work? Effects typically begin within 30–60 minutes.
Market and Availability
- Where to buy PT‑141: Available by prescription in the US in https://neurolabresearches.com/
- Pricing trends: Costs vary depending on insurance coverage.
- Global regulations: Approved in the US, under review in other regions.
📊 PT‑141™ Clinical Trial Data Summary
FDA Approval Trials (Women with HSDD)
| Study |
Population |
Dosage |
Outcome |
Reported Side Effects |
| Phase III RECONNECT Trials |
1,200+ premenopausal women |
1.75 mg SC injection |
Significant improvement in sexual desire scores (FSFI‑D) |
Nausea (40%), flushing (20%), headache (11%), injection site reactions (3%) |
| Long‑term Safety Study |
600+ women |
1.75 mg SC injection, up to 8 doses/month |
Sustained improvement in sexual desire over 12 months |
Nausea (36%), increased blood pressure (rare), fatigue (8%) |
Male Erectile Dysfunction Research
| Study |
Population |
Dosage |
Outcome |
Reported Side Effects |
| Pilot ED Study |
200 men with ED unresponsive to PDE5 inhibitors |
1.25–2 mg SC injection |
Improved erectile response in 60% of participants |
Nausea (25%), flushing (15%), headache (10%) |
| Combination Therapy Trial |
150 men |
PT‑141 + Sildenafil |
Enhanced erectile response compared to Sildenafil alone |
Similar side effect profile, slightly higher nausea |
Safety Profile Summary
| Category |
Details |
| Most common side effect |
Nausea (up to 40% of participants) |
| Moderate risks |
Flushing, headache, dizziness |
| Serious risks |
Increased blood pressure, contraindicated in uncontrolled hypertension |
| Long‑term data |
Limited, but sustained efficacy observed in women over 12 months |
PT‑141™ vs Other Therapies (Data Comparison)
| Therapy |
Approval |
Mechanism |
Reported Efficacy |
Common Side Effects |
| PT‑141™ (Vyleesi®) |
FDA approved (2019) |
Melanocortin receptor agonist |
Significant improvement in FSFI‑D scores |
Nausea, flushing, headache |
| Viagra (Sildenafil) |
FDA approved (1998) |
PDE5 inhibitor |
70–80% efficacy in ED |
Headache, flushing, nasal congestion |
| Cialis (Tadalafil) |
FDA approved (2003) |
PDE5 inhibitor |
70–80% efficacy in ED, longer duration |
Back pain, flushing, headache |
| Addyi (Flibanserin) |
FDA approved (2015) |
Serotonin receptor modulator |
Modest improvement in HSDD |
Dizziness, somnolence, hypotension |
📌 Evidence‑Based Summary
PT‑141™ (Bremelanotide) is a melanocortin receptor agonist peptide approved by the FDA in 2019 for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Clinical trials demonstrated statistically significant improvements in sexual desire scores, with nausea being the most common side effect. Research in men with erectile dysfunction shows promise, especially in those unresponsive to PDE5 inhibitors, with combination therapy enhancing outcomes.
Compared to traditional PDE5 inhibitors, PT‑141™ offers a unique neurogenic mechanism of action, stimulating sexual desire through the brain rather than vascular pathways. Its approval marks a milestone in sexual health, though careful monitoring is required due to side effects like nausea and blood pressure changes.
Conclusion
PT‑141™ is a groundbreaking peptide therapy that addresses sexual dysfunction through neurogenic pathways rather than vascular mechanisms. Its FDA approval for women with HSDD highlights its clinical importance, while ongoing research explores broader applications in men and mental health. With unique benefits and specific safety considerations, PT‑141™ represents a new frontier in peptide‑based therapies.
